Agaricus blazei extract (FA‑2‑b‑β) induces apoptosis in chronic myeloid leukemia cells
Agaricus blazei Murill (AbM) is a mushroom belonging to the Basidiomycetes family, which is believed to have antitumor and antioxidative activities. Proteoglycans and ergosterol are considered the key compounds of AbM for antitumor properties and so are used in complementary and alternative medicine...
Saved in:
Published in | Oncology letters Vol. 20; no. 5; p. 1 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Athens
Spandidos Publications
01.11.2020
Spandidos Publications UK Ltd D.A. Spandidos |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Agaricus blazei Murill (AbM) is a mushroom belonging to the Basidiomycetes family, which is believed to have antitumor and antioxidative activities. Proteoglycans and ergosterol are considered the key compounds of AbM for antitumor properties and so are used in complementary and alternative medicine as an anticancer drug. AbM is used to avoid serious side effects that would inevitably affect patients. Currently, the efficacy of AbM against chronic myeloid leukemia (CML) has not been established. The present study aimed to investigate the antitumor activities of the acidic RNA protein complex, FA-2-b-[beta], extracted from wild edible AbM. The CML K562 cells or primary CML bone marrow (BM) cells were treated with FA-2-b-[beta] at different concentrations and time points. CML cell line proliferation and apoptosis were determined using the CCK-8 assay or Annexin V/propidium iodide (PI) labeling, RT-qPCR and western blotting was performed to determine the involvement of the Wnt/[beta]-catenin-associated apoptotic pathway. The results of the present study demonstrated that FA-2-b-[beta] has a high anti-proliferative potency and strong pro-apoptotic effects. Thus, daily intake of mushrooms containing FA-2-b-[beta] may be an adequate source as an alternative medicine in the management of CML, and may provide useful information for the development of a novel therapeutic target in this area. Key words: CML, AbM, Wnt/[beta]-catenin signaling pathway, apoptosis cycle |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1792-1074 1792-1082 |
DOI: | 10.3892/ol.2020.12133 |